TITLE

Rivaroxaban being tested in patients with arrhythmia disorders in ROCKET AF trial

PUB. DATE
November 2008
SOURCE
Cardiology Today;Nov2008, Vol. 11 Issue 11, p11
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports that the ROCKET AF clinical trial investigated the safety and efficacy of rivaroxaban compared to warfarin in treating patients with arrhythmia disorders in the U.S. The trial will involve at least 14,000 persons who will be randomly assigned to rivaroxaban or warfarin during a crossover study in 272 study centers. Since formation of blood clot is being prevented and though warfarin is effective in blood clot prevention, Dr. Yousef Mohammad hopes that the trial will result in another treatment option for patients.
ACCESSION #
35639342

 

Related Articles

  • BRIDGE. Nichols, Emma Hitt; Ortel, Thomas L. // MD Conference Express;Aug2015, Vol. 15 Issue 21, p6 

    In the BRIDGE trial, bridging with low molecular weight heparin in patients with atrial fibrillation who underwent surgery or an invasive procedure that required warfarin interruption resulted in similar rates of arterial thromboembolism but significantly higher rates of minor and major bleeding.

  • Apixaban trial results look promising. Elliott, William T. // Neurology Alert;Oct2011 Clinical Briefs, p1 

    The article discusses the results of the ARISTOTLE trial with the use of apixaban for the prevention of stroke in patients with atrial fibrillation (AF). The ARISTOTLE trial had a primary outcome of ischemic or hemorrhagic stroke, or systemic embolism. After median follow-up, the primary outcome...

  • Study reveals effectiveness of cryoablation in setting of atrioventricular nodal reentrant tachycardia. Ellis, Brian // Cardiology Today;Feb2011, Vol. 14 Issue 2, p11 

    The article discusses a clinical trial in Europe and China which demonstrated that cryoablation is as effective as radiofrequency catheter ablation as a short-term treatment for atrioventricular nodal reentrant tachycardia , although recurrence rate in cryoablation is higher.

  • A New Way To Reverse Excessive Blood Thinning from Warfarin.  // Annals of Internal Medicine;12/3/2002, Vol. 137 Issue 11, pI41 

    Presents a summary of an article published in the December 3, 2002, issue of 'Annals of Internal Medicine,' which determined whether a human-made agent that was originally developed to control bleeding in patients with hemophilia would reverse anticoagulation from warfarin. Methods used by...

  • Role of genetics in warfarin dosing a source of debate. Foster, Melissa // Hem/Onc Today;12/25/2013, Vol. 14 Issue 24, p28 

    The article discusses the clinical trials of the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT), and the Clarification of Optimal Anticoagulation through Genetics (COAG) regarding the utility of genetics in achievement of optimal warfarin dosing.

  • Clinical trial data provide 'divergent' conclusions about pharmacogenomic-guided warfarin dosing. Baker, William L. // Cardiology Today;Feb2014, Vol. 17 Issue 2, p23 

    The article discusses three published clinical trials which provide divergent conclusions about pharmacogenomic-guided dosing of warfarin and explores whether these would spell the end for warfarin initiation.

  • Data-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management. Reiffel, James A. // Journal of Cardiovascular Pharmacology & Therapeutics;Mar1996, Vol. 1 Issue 1, p79 

    The article emphasizes the significance of clinical trials to the clinical management of arrhythmia. Since the 1960s, clinical trials has greatly influenced the management of arrhythmias. The therapy for ventricular tachyarrhythmias is also influenced by clinical trials findings, including the...

  • Vernakalant: A novel agent for the termination of atrial fibrillation. Finnin, Miki // American Journal of Health-System Pharmacy;7/15/2010, Vol. 67 Issue 14, p1157 

    Purpose. The pharmacology, pharmacokinetics, safety, clinical efficacy, and role of intravenous vernakalant hydrochloride for the rapid conversion of atrial fibrillation (AF) to normal sinus rhythm are reviewed. Summary. Vernakalant, currently being evaluated by the Food and Drug Administration...

  • STUDY CITES CAUSES OF SEVERE BLEEDING IN WARFARIN PATIENTS. Hurley, Mary Lou // RN;Sep94, Vol. 57 Issue 9, p78 

    Reports on the procedure to prevent intracranial bleeding associated with warfarin (Coumadin) based on the study conducted by researchers in Boston. Maintenance of the patient's prothombin time ratio under 2; Mortality of patients who suffered intracerebral bleeding; Common symptoms; Risk...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics